State Street Corp Atai Life Sciences N.V. Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, State Street Corp holds 81,918 shares of ATAI stock, worth $178,581. This represents 0.0% of its overall portfolio holdings.

Number of Shares

81,918

Previous 81,060 1.06%

Holding current value

$178,581

Previous $107,000 11.21%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$1.16 - $1.64 $995 - $1,407	858 Added 1.06%	81,918 $95,000
Q1 2024 May 15, 2024	SELL	$1.5 - $2.19 $9,027 - $13,179	-6,018 Reduced 6.91%	81,060 $159,000
Q4 2023 Feb 14, 2024	SELL	$1.04 - $1.55 $808,583 - $1.21 Million	-777,484 Reduced 89.93%	87,078 $122,000
Q3 2023 Nov 14, 2023	SELL	$1.27 - $2.28 $17,345 - $31,140	-13,658 Reduced 1.56%	864,562 $1.12 Million
Q2 2023 Aug 14, 2023	BUY	$1.44 - $2.19 $581,271 - $884,017	403,661 Added 85.06%	878,220 $1.51 Million
Q1 2023 May 15, 2023	BUY	$1.17 - $2.7 $29,980 - $69,184	25,624 Added 5.71%	474,559 $858,000
Q4 2022 Feb 14, 2023	BUY	$2.38 - $3.55 $814,212 - $1.21 Million	342,106 Added 320.24%	448,935 $1.19 Million
Q3 2022 Nov 15, 2022	BUY	$3.14 - $4.87 $170,118 - $263,846	54,178 Added 102.9%	106,829 $354,000
Q2 2022 Aug 15, 2022	SELL	$3.03 - $5.32 $43,435 - $76,262	-14,335 Reduced 21.4%	52,651 $192,000
Q1 2022 May 16, 2022	BUY	$4.66 - $7.66 $11,510 - $18,920	2,470 Added 3.83%	66,986 $341,000
Q4 2021 Feb 14, 2022	BUY	$6.82 - $17.8 $439,999 - $1.15 Million	64,516 New	64,516 $492,000

Others Institutions Holding ATAI

# of Institutions

Shares Held

12.4M

Call Options Held

77.8K

Put Options Held

50.3K

View Full List

About ATAI Life Sciences N.V.

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $362M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

More about ATAI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Atai Life Sciences N.V. Transaction History